Showing results (71-80 of 105) with videos related to
Sort By:
Pageof 11
European Journal of Clinical Pharmacology|February 7, 2002
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitroU Yasar, E Eliasson, C Forslund-Bergengren, et al.European Journal of Clinical Pharmacology|February 24, 2001
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patientsM G Scordo, E Spina, P Romeo, et al.Pharmacogenetics|October 1, 1996
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean populationH K Roh, M L Dahl, I Johansson, et al.Journal of Internal Medicine|November 1, 1996
Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a causal relationship?L L Gustafsson, L S Eriksson, M L Dahl, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 16, 2001
Role of CYP2C9 polymorphism in losartan oxidationYasar U, G Tybring, M Hidestrand, et al.Clinical Pharmacology and Therapeutics|June 1, 1989
Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beingsM L Dahl-Puustinen, T L Perry, E Dumont, et al.Clinical Pharmacology and Therapeutics|August 1, 1994
Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphismM L Dahl, G Tybring, C E Elwin, et al.British Journal of Clinical Pharmacology|June 20, 2003
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with CaucasiansP Dalén, M-L Dahl, H-K Roh, et al.Clinical Pharmacology and Therapeutics|November 3, 1998
CYP2D6 polymorphism is not crucial for the disposition of selegilineH Scheinin, M Anttila, M L Dahl, et al.Therapeutic Drug Monitoring|August 15, 2000
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urineJ A Carrillo, M Christensen, S I Ramos, et al.Pageof 11